Shield Therapeutics PLC Directorate Change (2651Q)

TIDMSTX

RNS Number : 2651Q

Shield Therapeutics PLC

05 June 2018

Shield Therapeutics plc

("Shield" or the "Company")

Directorate Change

London, UK, 5 June 2018. Shield Therapeutics plc (LSE:STX), announces that Dr Andrew Heath has notified the Company of his intention to step down as Chairman, and from the Board, by not standing for re-election at the upcoming AGM so that he may focus on other business interests. Dr Heath has worked closely with Shield Therapeutics since 2015, initially as a senior advisor, before joining the Board as Non-Executive Chairman in early 2016. During this time, he has played a key role in helping the Company to successfully achieve an initial public offering on the London Stock Exchange and has been integral to the subsequent development of the Company.

A process to appoint a successor is underway.

Carl Sterritt, Chief Executive Officer of Shield Therapeutics commented "On behalf of the Board, I would like to thank Andrew for his considerable contribution to the development and transformation of Shield Therapeutics from a private, development stage company to a commercially-focused and publicly listed entity. His experienced counsel during this period of significant transition for the Company has been greatly appreciated and I offer him our best wishes."

Dr Andrew Heath, Non-Executive Chairman, said "I have thoroughly enjoyed my time at Shield Therapeutics and am proud to have been at the head of the team that has built the Company into a commercial stage publicly listed specialty pharmaceutical company. Through its people and assets Shield has the foundations in place for a successful future and I wish Carl and the team the very best of luck with their ongoing endeavours."

-Ends-

For further information please contact:

Shield Therapeutics plc [phone]

Carl Sterritt, Chief Executive Officer

Karl Keegan, Chief Financial Officer

Nominated Advisor and Joint Broker [phone]

Liberum Capital Limited

Christopher Britton/Steve Pearce

Joint Broker [phone]

Peel Hunt LLP

James Steel/Christopher Golden

Financial PR Advisor [phone]

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal

About Shield Therapeutics plc

Shield Therapeutics is a commercial stage pharmaceutical company, delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru(R), for the treatment of all adults with iron deficiency with or without anaemia which has exclusive IP rights until the mid-2030's. For more information please visit www.shieldtherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOAZMGGVGDFGRZZ

(END) Dow Jones Newswires

June 05, 2018 02:01 ET (06:01 GMT)